



Date: 10SEP2021

Eresina LLC - 0724.1, A Study of the Safety of Progeneron Hand Cream in Subjects with Palmar Fibromatosis

Principal Investigator: Raymond Raven, MD

Data Analysis:

The percent of subjects with adverse events and serious adverse events will be reported. **Results: 0 % (There were no reported adverse events or serious adverse events that were reported during the study)**

The adverse and serious adverse events will be characterized by their type, location, and severity. **Results: None (Characterization by type, location, and severity of adverse events cannot be assessed as there are no adverse events that were reported)**

Adverse and serious adverse events will be analyzed and reported by demographic characteristics (eg, the % of patients younger than 65 with and adverse event vs. the % of patient greater/equal 65. **Results: None (Characterization of adverse events cannot be assessed as there are no adverse events that were reported)**

Raymond Raven, MD
Principal Investigator

09/14/2021

Date